{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000000", "text": "# ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "section": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "page_from": null, "page_to": null, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ba1fc831a77c0bc21f7bfa667d26d5dd672130a2e89b1db2a90eb33cf86dfd19"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000001", "text": "FERTILITY-SPARING\nTREATMENT\nCervical cancer\nOvarian cancer\nBorderline ovarian\ntumours\nPOCKET\nGUIDELINES\nPUBLISHED IN 2024", "section": "FERTILITY-SPARING", "page_from": 1, "page_to": 1, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3269b5830a30d41ac45563986f2a3a2d0951a312517c4001b30c1624fc264707"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000002", "text": "2", "section": "FERTILITY-SPARING", "page_from": 2, "page_to": 2, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d4735e3a265e16eee03f59718b9b5d03019c07d8b6c51f90da3a666eec13ab35"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000003", "text": "3\nPOCKET GUIDELINES\nBased on\nESGO-ESHRE-ESGE guidelines\nfor the fertility-sparing treatment\nand follow-up in patients with cervical\ncancer, ovarian cancer, and borderline\novarian tumours\nMorice, P., Scambia, G., … Grynberg, M. (2024). Fertility-sparing treatment and follow-up\nin patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines\nfrom ESGO, ESHRE, and ESGE. Lancet Oncology. Nov;25(11):e602-e610.\ndoi: 10.1016/S1470-2045(24)00262-6", "section": "POCKET GUIDELINES", "page_from": 3, "page_to": 3, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a04fdd9e1400a0f8636736cdd1eaad04962b7c9325ab6fc3250046fb49002670"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000004", "text": "4\nA strong collaboration was established between the European Society of Gynaecolo-\ngical Oncology (ESGO), the European Society of Human Reproduction and Embryo-\nlogy (ESHRE), and the European Society for Gynaecological Endoscopy (ESGE), ai-\nming to develop clinically relevant and evidence-based guidelines focusing on key\naspects of fertility-sparing treatments of patients with gynaecological malignancies.\nA first Pocket Guideline focusing on endometrial carcinoma was published in 2023.\nIn this Pocket Guideline, three main topics are addressed:\n1. The indications of fertility-sparing treatment including conservative surgeries, stage-by-\n-stage and histotype-by-histotype (if required); focusing on ovarian tumours (ie, borderline,\nnon-epithelial, and epithelial cancers) and cervical cancers in which modalities and indica-\ntions of conservative treatments are highly debated.\n2. The optimisation of fertility results and management of infertility if occurred.\n3. The aftercare management, which presents major practical questions.\nFertility-sparing surgery, in these ESGO/ESHRE/ESGE guidelines, is based on the preservation", "section": "POCKET GUIDELINES", "page_from": 4, "page_to": 4, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ab2dacabc6957c6ab52f3c09d708a7be181d1a5dd941b41f9b5e321b428983c6"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000005", "text": "3. The aftercare management, which presents major practical questions.\nFertility-sparing surgery, in these ESGO/ESHRE/ESGE guidelines, is based on the preservation\nof the uterus and at least one part of one ovary, with the aim to achieve (spontaneous)\npregnancy. When both ovaries are macroscopically involved (or at greater oncological risk\nof bilateral spread) in ovarian tumours, isolated uterine preservation (with bilateral sal-\npingo-oophorectomy) is discussed. Tumour histological subtypes and staging are defined\naccording to the WHO Classification of Tumours and the International Federation of Gyne-\ncology and Obstetrics (FIGO) staging systems (2021 for the ovary, tube, and peritoneum,\nand 2019 for the cervix).\nThe guidelines were developed using a five-step process as defined by the ESGO Guideline\nCommittee:\nNomination of multidisciplinary international development group\nIdentification of scientific evidence\nFormulation of guidelines\nExternal evaluation of guidelines (international review)\nIntegration of international reviewers’ comments\nThe objectives of these ESGO/ESHRE/ESGE guidelines are to improve the quality of ferti-", "section": "POCKET GUIDELINES", "page_from": 4, "page_to": 4, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "25ea05f944ef7be463be4f8c9d50623803806d56ac9470f215e61064a64d3ba0"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000006", "text": "External evaluation of guidelines (international review)\nIntegration of international reviewers’ comments\nThe objectives of these ESGO/ESHRE/ESGE guidelines are to improve the quality of ferti-\nlity-sparing strategies in ovarian and cervical cancers and harmonise them to be used by\nall health professionals involved in the fertility-sparing treatment of patients with cervical\ncancers, ovarian cancers, or borderline ovarian tumours, across all allied disciplines.", "section": "POCKET GUIDELINES", "page_from": 4, "page_to": 4, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fb8ab8c9a426aa24ef9ef79c57236c2e6f9db48bd6d45475161cf56fb706822a"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000007", "text": "5\nI\nEvidence from at least one large randomised, controlled trial of good methodologi-\ncal quality (low potential for bias) or meta-analyses of well conducted, randomised\ntrials without heterogeneity\nII\t Small randomised trials or large randomised trials with a suspicion of bias (lower\nmethodological quality) or meta-analyses of such trials or of trials with demonstra-\nted heterogeneity\nIII\t Prospective cohort studies\nIV\t Retrospective cohort studies or case-control studies\nV\t Studies without control group, case reports, expert opinions\nLEVELS OF EVIDENCE\nA\t Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended\nB\t Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, gene-\nrally recommended\nC\t Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the dis-\nadvantages (adverse events, costs…), optional\nD\t Moderate evidence against efﬁcacy or for adverse outcome, generally not recom-\nmended\nE\t Strong evidence against efﬁcacy or for adverse outcome, never recommended\nGRADES OF RECOMMENDATIONS\nThese guidelines exclude the procedures used to protect gonads and maintain endo-", "section": "I", "page_from": 5, "page_to": 5, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "94653a0567e686ebad7191d0b5c19bb1ae56a800bf16ec709081046ad90b692c"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000008", "text": "mended\nE\t Strong evidence against efﬁcacy or for adverse outcome, never recommended\nGRADES OF RECOMMENDATIONS\nThese guidelines exclude the procedures used to protect gonads and maintain endo-\ncrine functions of the ovaries (ovarian transposition, gonadotrophin hormone-releasing\nhormone agonists, etc), combined with ovarian transposition, uterine transplantation,\nand surrogate pregnancy. Gonadotoxicity induced by systemic or radiotherapies are not\ncovered. These guidelines do not include any economic analysis of the strategies. Any\nclinician seeking to apply or consult these guidelines is expected to use independent\nmedical judgment in the context of individual clinical circumstances to determine any\npatient’s care or treatment.\nTo ensure that the statements were evidence based, the current literature was reviewed\nand critically appraised. A systematic, unbiased literature review of relevant studies pub-\nlished between January 2003 and June 2023 was carried out.\nThe guidelines were adopted if they were supported by sufficient high level of scientific\nevidence and/or when a large consensus among experts was obtained. An adapted ver-", "section": "I", "page_from": 5, "page_to": 5, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e2bea87e430d8434d2b72460f404e248c03670cd5520ac17f82ee2592759e8f8"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000009", "text": "The guidelines were adopted if they were supported by sufficient high level of scientific\nevidence and/or when a large consensus among experts was obtained. An adapted ver-\nsion of the “Infectious Diseases Society of America-United States Public Health Service\nGrading System” was used to define the level of evidence and grade of recommendation\nfor each of the recommendations:", "section": "I", "page_from": 5, "page_to": 5, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3ef6ee0222324bc47a2835d0e3ec7b235886b3b6223b60db91e92855ef7782d2"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000010", "text": "6\nNAME\nSPECIALTY\nAFFILIATION\nPhilippe Morice\nGynecologic oncologist (chair)\nGustave Roussy Cancer Campus, Villejuif (France)\n\nUniversité Paris Saclay, Paris (France)\nGiovanni Scambia\nEndoscopist, surgeon (chair)\nFondazione Policlinico Universitario A Gemelli\n\nIRCCS, Rome (Italy)\nMichaël Grynberg\nOnco-fertility specialist (chair)\nUniversité Paris Saclay, Paris (France)\n\nHôpital Antoine Béclère, Clamart (France)\n\nHôpital Jean Verdier, Bondy (France)\nFrançois Planchamp\nMethodologist\nInstitut Bergonié, Bordeaux, (France)\nNadeem R Abu-Rustum\nGynecologic oncologist\nMemorial Sloan Kettering Cancer Center,\n\nNew York, NY (USA)\nMaribel Acien\nReproductive surgeon\nInstitute of Women’s Health, University College\n\nLondon, London (UK),\n\nMiguel Hernandez University, Alicante (Spain)\nAlessandro Arena\nGynecologist\nIRCCS, Azienda Ospedaliero Univeristaria di\n\nBologna, Bologna (Italy), University of Bologna,\n\nBologna (Italy)\nSara Brucker\nGynecologic oncologist\nUniversity of Tübingen, Tübingen (Germany)\n\nUniversity Hospital Tübingen, Tübingen (Germany)\nYing Cheong\nReproductive medicine specialist\t Faculty of Medicine, University of Southampton,\n\nSouthampton (UK)\nPierre Collinet\nGynecologist", "section": "NAME", "page_from": 6, "page_to": 6, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "088753fe7ffbfb58d3db063dd7b53719a11e99e4a6f0d43a09881faa4911f040"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000011", "text": "University Hospital Tübingen, Tübingen (Germany)\nYing Cheong\nReproductive medicine specialist\t Faculty of Medicine, University of Southampton,\n\nSouthampton (UK)\nPierre Collinet\nGynecologist\nHôpital Privé le Bois, Groupe Ramsay Lille\n\nMetropole, Lille (France)\nFrancesco Fanfani\nGynecologic oncologist\nFondazione Policlinico Universitario A Gemelli\n\nIRCCS, Rome (Italy)\nFrancesca Filippi\nGynecologist\nFondazione IRCCS Ca’ Granda Ospedale\n\nMaggiore Policlinico, Milan (Italy)\nAne Gerda Zahl Eriksson\t Gynecologic oncologist\nThe Norwegian Radium Hospital, Oslo University\n\nHospital, Oslo (Norway)\nSebastien Gouy\nGynecologic oncologist\nGustave Roussy Cancer Campus, Villejuif\n\n(France) Université Paris Saclay, Paris (France)\nESGO would like to thank the members of the international development group for\ntheir constant availability, work, and for making possible the development of these\nguidelines for the fertility-sparing treatment and follow-up in patients with cervical\ncancer, ovarian cancer, and borderline ovarian tumours (see below). ESGO is also very\ngrateful to the 121 international external reviewers for their participation (list available\non the ESGO website).", "section": "NAME", "page_from": 6, "page_to": 6, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "42815e7ac2b2ba69d898840132904f0e1ba6ec0cd6571835d9853f3d27ccc905"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000012", "text": "7\nNAME\nSPECIALTY\nAFFILIATION\nPhilipp Harter\nGynecologic oncologist\nKliniken Essen Mitte, Essen (Germany)\nXavier Matias-Guiu\nPathologist\nHospital Universitari Arnau de Vilanova,\n\nLleida (Spain)\nGeorge Pados\nObstetrician & gynecologist\nPapageorgiou General Hospital,\n\nSchool of Medicine, Aristotle University\n\nof Thessaloniki, Thessaloniki (Greece)\nMaja Pakiz\nGynecologic oncologist\nUniversity Medical Center Maribor, Maribor\n\n(Slovenia)\nDenis Querleu\nGynecologic oncologist\nFondazione Policlinico Universitario A Gemelli\n\nIRCCS, Rome (Italy)\nAlexandros Rodolakis\nGynecologic oncologist\nAlexandra Hospital, National and Kapodistrian\n\nUniversity of Athens, Athens (Greece)\nChristine Rousset-Jablonski\t Medical oncologist\nCentre Léon Bérard, Lyon (France)\n\nHôpital Femme Mère Enfant, Bron (France)\nArtem Stepanyan\nGynecologic oncologist\nNairi Medical Center, Yerevan (Armenia)\nAntonia Carla Testa\nGynecologic oncologist\nFondazione Policlinico Universitario A Gemelli\n\nIRCCS, Rome (Italy)\nKirsten Tryde Macklon\nOnco-fertility specialist\nCopenhagen University Hospital, Copenhagen\n\n(Denmark)\nDimitrios Tsolakidis\nObstetrician & gynecologist\nPapageorgiou General Hospital,", "section": "NAME", "page_from": 7, "page_to": 7, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8011aa89febe12010a82ac77df5d2e34051ac1385968853af095928978733d49"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000013", "text": "Kirsten Tryde Macklon\nOnco-fertility specialist\nCopenhagen University Hospital, Copenhagen\n\n(Denmark)\nDimitrios Tsolakidis\nObstetrician & gynecologist\nPapageorgiou General Hospital,\n\nSchool of Medicine, Aristotle University\n\nof Thessaloniki, Thessaloniki (Greece)\nMichel De Vos\nReproductive medicine specialist\t Centre for Reproductive Medicine, University\n\nHospital Brussels, Brussels (Belgium)\n\nVrije Universiteit Brussel, Brussels (Belgium)", "section": "NAME", "page_from": 7, "page_to": 7, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d40f91bc60b6fd917665bf0d96574e20722717072d53f5b7d9c81a9705a3f83d"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000014", "text": "8\nTABLE OF CONTENTS\nGeneral recommendations ..................................................................... 10\nOncologic aspects of fertility-sparing strategies during\nthe initial management of cervical cancer ............................................ 12\nOncologic selection criteria...................................................................... 12\nMethods to assess the criteria ................................................................. 12\nSurgical and pathological criteria............................................................. 12\nFavourable oncologic selection criteria..................................................... 13\nUnfavourable oncologic selection criteria................................................. 14\nOncologic selection criteria acceptable in selected cases ......................... 14\nNeoadjuvant chemotherapy for selected patients\nwith stage IB2 cervical cancer ................................................................. 15\nOncologic aspects of fertility-sparing strategies\nduring the initial management of ovarian cancer ............................... 15", "section": "TABLE OF CONTENTS", "page_from": 8, "page_to": 8, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ab3f16f24ceda2976cbbf0a3ee2e2aa74dc36f63872933a4b2afb27f5dec2c62"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000015", "text": "Oncologic aspects of fertility-sparing strategies\nduring the initial management of ovarian cancer ............................... 15\nGeneral recommendation........................................................................ 15\nOncologic selection criteria (see Table 1) ................................................. 15\nFavourable oncologic selection criteria for ovarian preservation................ 15\nUnfavourable oncologic selection criteria for ovarian preservation............ 16\nOncologic selection criteria acceptable in selected cases ......................... 16\nSalpingo-oophorectomy vs. cystectomy in selected cases\nof borderline ovarian tumours................................................................. 18\nOptimisation of fertility results and infertility management ............. 18\nReproductive medicine specialist consultation.......................................... 18\nReproductive medicine specialist consultation in patients\nwith ovarian cancer and high-risk genetic predisposition.......................... 18\nEvaluating ovarian function in patients before cancer treatment? ........... 19", "section": "TABLE OF CONTENTS", "page_from": 8, "page_to": 8, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f1117c0a2d53a44c849117a1aaaebc2ad1d658ed432deac5cfe2a3a63426a598"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000016", "text": "with ovarian cancer and high-risk genetic predisposition.......................... 18\nEvaluating ovarian function in patients before cancer treatment? ........... 19\nFertility preservation methods in first line treatment settings ..................  19\nOvarian tumours ..................................................................................... 19", "section": "TABLE OF CONTENTS", "page_from": 8, "page_to": 8, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1d12def510bc69b7cda2eef3cea8a0363325a32d7bfceb000a171e8758c475b1"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000017", "text": "9\nCevical cancers ....................................................................................... 20\nFertility preservation methods in case of recurrence................................. 20\nEvaluating ovarian function....................................................................  21\nWhat should be offered to patients after treatment? .............................  21\nDesire for immediate pregnancy ............................................................. 21\nNo immediate pregnancy desired ............................................................ 21\nOocyte vitrification ................................................................................. 22\nDesire for a pregnancy and beyond ...................................................... 22\nWhen should oncological authorisation be granted? ............................... 22\nCervical cancer........................................................................................ 23\nFrequencies of follow-up after fertility-sparing management ................... 23\nFollow-up procedures after fertility-sparing management........................ 23\nSpecific requirements for the follow-up during the pregnancy", "section": "TABLE OF CONTENTS", "page_from": 9, "page_to": 9, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "dd9dc0b33f2f42db0154e8d81c7773fedb152367070ca071433b2900f3b259dc"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000018", "text": "Follow-up procedures after fertility-sparing management........................ 23\nSpecific requirements for the follow-up during the pregnancy\nand maternal surveillance........................................................................ 23\nNeed for completion surgery after childbearing ...................................... 24\nIndication and modalities for hormone replacement therapy\nafter completion surgery  or bilateral salpingo-oophorectomy\nplus uterine preservation ........................................................................ 24\nOvarian cancer ....................................................................................... 24\nFrequencies of follow-up after fertility-sparing management.................... 24\nSurveillance during pregnancy ................................................................ 25\nNeed for a completion surgery after childbearing .................................... 25\nIndications and modalities for hormone replacement therapy\nafter completion surgery or bilateral salpingo-oophorectomy\nplus uterine preservation ........................................................................ 25", "section": "TABLE OF CONTENTS", "page_from": 9, "page_to": 9, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "73329a6a602a6f79621ead3fb482ee69ea92b47503630fd8ea22cbc1f1b029d0"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000019", "text": "10\nGeneral recommendations\nCounselling with a reproductive specialist who has an in-depth understan-\nding of the patient and couple’s history is recommended before considering\nfertility-sparing treatment and pregnancy seeking\nThe aim of fertility-sparing surgery is to enable patients to have unassisted\nor assisted pregnancies with their uterus and their own or donated oocytes.\nFertility-sparing surgery and treatment planning should be performed\nexclusively by teams with a strong collaboration between gynaecological\noncologists and reproductive medicine specialists.\nPathological expert review is recommended in all patients if the diagnosis\nand associated treatment could impair fertility.\nDetailed description of the initial surgery should be provided (endobag,\nupper abdomen description, etc).\nA\nA\nA\nA\nA\nThe main steps for the selection of patients with cervical cancer for considering fertility-\n-sparing treatment are described in figure 1.", "section": "General recommendations", "page_from": 10, "page_to": 10, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "148bff5204ba5e2e9136ec85600bcd0e510d8009ff1bf839dd3a47e906fa0a78"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000020", "text": "11\nFigure 1\nSelection of patients with cervical cancer for fertility-sparing\ntreatment\nFertility-sparing treatment\nDesirous of future fertility\nYES\nYES\nNO\nSquamous cell carcinomas or HPV associated usual\ntype adenocarcinomas\nRadiological1 and\nsurgical LN staging\nFertility-sparing treatment\ncannot be recommended\nNegative LN\nTumour size\nFertility-sparing treatment cannot\nbe performed or recommended\n≤2 cm\n>4 cm\n2-4 cm\nSuitable candidate\nfor fertility-sparing\ntreatment\nFertility-sparing treatment\ncan be considered in\nselected cases2\nFertility-sparing treatment\ncannot be considered\na standard treatment2\nYES\nNO\nLN lymph node\n1 Pelvic magnetic resonance imaging (preferred, evaluated by a dedicated gynaecological radiolo-\ngist) and/or expert sonography are mandatory imaging tests. Radiological assessment by computed\ntomography or positron emission tomography/computed tomography could be performed to\nexclude any distant metastatic disease;\n2 Pelvic lymph node staging (sentinel lymph node) should always be the first step in each\nfertility-sparing therapy procedure (except for T1a1 lymphovascular space involvement negative", "section": "Figure 1", "page_from": 11, "page_to": 11, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "951a5e17065a1133fd93485c18c71f425865a676430016261c851bb1689250eb"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000021", "text": "2 Pelvic lymph node staging (sentinel lymph node) should always be the first step in each\nfertility-sparing therapy procedure (except for T1a1 lymphovascular space involvement negative\ndisease). All sentinel lymph nodes from both sides of the pelvis and any suspicious LN should\nbe sent for frozen section. If sentinel lymph node cannot be detected on either pelvic side,\na systematic pelvic lymphadenectomy should be performed on that side. Intraoperative\nassessment of LN status is highly recommended.", "section": "Figure 1", "page_from": 11, "page_to": 11, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8d82e43f2ae08fc2cbbd4c7551634016062e5ea5980d8ea8c17529f402ac48f9"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000022", "text": "12\nOncologic selection criteria\nOncologic aspects of fertility-sparing strategies during the initial\nmanagement of cervical cancer\nMethods to assess the criteria\nThe mandatory imaging tests to assess oncological criteria are pelvic mag-\nnetic resonance (MRI) (preferred; evaluated by a dedicated gynaecological\nradiologist) or expert sonography. The following information is required:\ntumour size, depth of stromal invasion, distance between cranial edge of\ntumour and internal cervical orifice, and any extra cervical extension or suspi-\ncious nodes.\nRadiological assessment by computed tomography (CT) or positron emis-\nsion tomography/computed tomography (PET/CT) could be performed to\nexclude any distant metastatic disease.\nCervical conisation is the method of choice for staging in early cervical can-\ncer and could be associated with lymph node staging according to the\nESGO-ESTRO-ESP guidelines.\nConisation should be performed if no gross lesion is noted.\nA\nB\nB\nB\nSurgical and pathological criteria\nRadical trachelectomy with removal of a part of parametria is not recom-\nmended for stage IB1 disease fulfilling all the strict inclusion criteria of the", "section": "Oncologic selection criteria", "page_from": 12, "page_to": 12, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c0f8986f4049d2382560bab2da13f79b580ef16c9141c7bfdeff81c7aa571968"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000023", "text": "A\nB\nB\nB\nSurgical and pathological criteria\nRadical trachelectomy with removal of a part of parametria is not recom-\nmended for stage IB1 disease fulfilling all the strict inclusion criteria of the\nConCerv trial (ie, stage IA2-IB1 as defined by the 2009 FIGO staging system,\nsquamous cell at any grade or adenocarcinoma at grade 1 or 2, tumour\nsize ≤2 cm, no lymphovascular space invasion (LVSI), negative imaging for\nmetastatic disease, depth of invasion ≤10 mm, and conisation margins and\nendocervical curettage negative for malignancy or high-grade dysplasia.\nRadical trachelectomy is recommended for stage IB2 disease by use of an\nabdominal approach (eg, laparotomy or mini-invasive approaches [robotic-\n-assisted or pure laparoscopic approaches]).\nLymph node staging strategies for stage IB1 and IB2 diseases should follow\nthe ESGO-ESTRO-ESP guidelines.\nNegative margins (a non-fragmented specimen, with at least 1 mm histolo-\ngical-free margin from carcinoma or dysplasia) are mandatory.\nE\nB\nB\nA", "section": "Oncologic selection criteria", "page_from": 12, "page_to": 12, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4741cd51c4738dc853e4ac37eed59ce6cb095101512312065386719571a6d00c"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000024", "text": "13\nA non-fragmented cone is crucial for pathological evaluation. The base of\nthe cone should encompass the visible gross lesion on the ectocervix with at\nleast 1 mm histological margin. The height of the cone (centre of cone base\nto vertex) should be at least 10 mm. Cones can be oriented with a suture at\nthe midpoint of the anterior cervical lip (also called the 12 o’clock suture).\nA negative endocervical biopsy or curettage above the conisation or trache-\nlectomy is required.\nPathologists are encouraged to assign a Silva pattern classification for hu-\nman papillomavirus (HPV)-associated usual-type adenocarcinoma tumours\n(pattern A is the most favourable; pattern B without LVSI is also favourable).\nNegative pelvic nodal status is mandatory for any fertility-sparing therapy.\nFor assessing the pelvic nodal staging, ESGO-ESTRO-ESP guidelines should\nbe followed.\nPelvic nodal staging is not indicated in T1a1 LVSI-negative tumours that\nhave negative margins on conisation.\nIntraoperative frozen section of cone margins can be considered to tailor\nthe surgery.\nB\nC\nD\nB\nB\nA\nFavourable oncologic selection criteria\nThe following seven criteria should be met before considering fertility-spa-", "section": "Oncologic selection criteria", "page_from": 13, "page_to": 13, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "84c83189437099ac623d48395d98b9c00075f8ea4c5c7ff9fba784167dcf1618"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000025", "text": "the surgery.\nB\nC\nD\nB\nB\nA\nFavourable oncologic selection criteria\nThe following seven criteria should be met before considering fertility-spa-\nring management:\n•\t Assignment of patients to favourable selection criteria is based on all\n\nclinicopathological variables;\n•\t Confirmed histology on cervical biopsy or conisation is consistent with\n\nsquamous cell carcinoma (all grades) or usual-type HPV-associated ade-\n\nnocarcinoma (all grades) with no more than 10 mm stromal invasion;\n•\t Absence of LVSI is a favourable pathological biomarker;\n•\t No evidence of any metastasis is required;\n•\t Largest measurement of a tumour is 2 cm by imaging or clinical exam;\n•\t Free margins on final pathology are mandatory;\n•\t No evidence of tumour involvement of the internal cervical orifice and\n\ncranial extent of cervical tumour is 1 cm or more from the internal cervi-\n\ncal orifice on imaging.\nB\nB\nB\nB\nA\nA\nB", "section": "Oncologic selection criteria", "page_from": 13, "page_to": 13, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2925d9bce791df6f61d20ed9ee1d7b36c85f42a4db7eb7e6024991762e328d28"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000026", "text": "14\nUnfavourable oncologic selection criteria\nAt least one of the following criteria should be met:\n•\t Any histological type other than squamous cell carcinoma and usual-type\n\nHPV-associated adenocarcinoma (mucinous-type HPV-associated carci-\n\nnomas, gastric-type cervical adenocarcinoma, mesonephric carcinoma,\n\nsmall-cell neuroendocrine carcinoma, and clear cell carcinoma;\n•\t Confirmed pelvic nodal involvement, extracervical tumour extension,\n\nevidence of tumour beyond the cervical ring, or metastasis;\n•\t The largest tumour measurement is more than 4 cm by imaging or clinical\n\nexam;\n•\t FIGO stage is IB3 or more;\n•\t Tumour cranial extent is less than 5 mm from, or involves, the internal\n\ncervical orifice or lower uterine segment by imaging;\n•\t Intraoperative frozen-section assessment of the resected cervical spe-\n\ncimen for assessing the upper resection margin reveals a positive margin\n\nfrom the internal cervical orifice with inability to achieve a wider margin;\n•\t Histologically confirmed endocervical margin, endocervical curettage\n\nabove resection, or endometrial involvement on final pathology.\nC\nB\nB\nB\nB\nB\nB\nOncologic selection criteria acceptable in selected cases", "section": "Unfavourable oncologic selection criteria", "page_from": 14, "page_to": 14, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "67b58a1450f7584cc1627cf12a2e8e43078074471534279aba40327189278f5e"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000027", "text": "above resection, or endometrial involvement on final pathology.\nC\nB\nB\nB\nB\nB\nB\nOncologic selection criteria acceptable in selected cases\nAt least one of the following criteria should be met:\n•\t Tumour size is 2-4 cm by exam or imaging;\n•\t Stromal invasion by conisation is more than 10 mm but has negative mar-\n\ngins;\n•\t Evidence of deep cervical stromal invasion on MRI or sonography;\n•\t Tumour cranial extent is 5–10 mm from internal cervical orifice by imaging;\n•\t Trachelectomy specimen margin reveals a 5–10 mm tumour-free margin\n\nfrom the internal cervical orifice;\n•\t Silva pattern C of HPV-associated usual-type adenocarcinoma (data are\n\nscarce on pattern B with LVSI).\nC\nC\nB\nB\nC\nC", "section": "Unfavourable oncologic selection criteria", "page_from": 14, "page_to": 14, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f144d825f606e566eaa96e4b54726158bddb95cc1f6072bf7f9f232cd8bc7e86"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000028", "text": "15\nNeoadjuvant chemotherapy for selected patients with stage IB2\ncervical cancer\nNeoadjuvant chemotherapy has been used by various investigators as an\nalternative to radical trachelectomy for selected patients with stage IB2 (2-4\ncm) cervical cancer.\nVarious chemotherapy regimens have been used to reduce cervical tumour\nburden and allow for a satisfactory resection of the primary tumour with\nconisation and simple or radical trachelectomy.\nRetrospective data suggest that abdominal radical trachelectomy has the\nlowest recurrence rate for patients with stage IB2 cervical cancer.\nOngoing prospective trials with platinum and paclitaxel will clarify the va-\nlidity of neoadjuvant chemotherapy in fertility-sparing treatment of stage\nIB2 disease.\nIncluding patients with stage IB2 cervical cancer in ongoing trials is encou-\nraged to evaluate the safety of neoadjuvant chemotherapy.\nConfirming pathological-negative bilateral pelvic nodes (sentinel lymph\nnode or lymphadenectomy) before starting neoadjuvant chemotherapy\nallows for the most accurate staging and selection of appropriate candida-\ntes for neoadjuvant chemotherapy approach.", "section": "Neoadjuvant chemotherapy for selected patients with stage IB2", "page_from": 15, "page_to": 15, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "13cc62c8df87b13da3647b8fb4ff5482a4d334a191aeb0dca97bd0bf803397d3"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000029", "text": "node or lymphadenectomy) before starting neoadjuvant chemotherapy\nallows for the most accurate staging and selection of appropriate candida-\ntes for neoadjuvant chemotherapy approach.\nPreoperative imaging with pelvic MRI and whole-body PET-CT is favoured.\nC\nC\nC\nC\nB\nB\nB\nGeneral recommendation\nOncologic aspects of fertility-sparing strategies during the initial\nmanagement of ovarian cancer\nIf bilateral oophorectomy is needed, uterine-sparing surgery can be consi-\ndered assuming normal endometrial (preferably evaluated by hysteroscopy)\nand serosal evaluation.\nB\nOncologic selection criteria (see Table 1)\nFavourable oncologic selection criteria for ovarian preservation\nOne of the following criteria should be met:\n•\t Borderline ovarian tumour all stages (non-invasive peritoneal implants)\n\nregardless of ovarian micro invasion;\n•\t Germ cell tumours (all stages);\nB", "section": "Neoadjuvant chemotherapy for selected patients with stage IB2", "page_from": 15, "page_to": 15, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a94c90b6821cb421552cdad259630cde9dcfe3fc44aa36ecaa1bf86eef6355fd"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000030", "text": "16\n•\t Granulosa cell tumours stage IA and IC1;\n•\t Sertoli-Leydig cell well-and-moderately differentiated tumours stage IA;\n•\t Low-grade serous and low grade endometrioid carcinomas stage IA and IC1;\n•\t High-grade serous carcinoma stage IA;\n•\t Mucinous carcinoma expansile subtype stage IA and IC1;\n•\t Mucinous carcinoma infiltrative stage IA;\n•\t Clear-cell carcinoma stage IA and IC1.\nB\nUnfavourable oncologic selection criteria for ovarian preservation\nOne of the following criteria should be met:\n•\t Invasive epithelial ovarian tumours stage IB and II–IV;\n•\t Low-grade serous carcinoma stage IC3;\n•\t Low-grade endometrioid carcinoma stage IC3;\n•\t High-grade serous and high-grade endometrioid carcinomas stage IC3;\n•\t Clear cell carcinoma stage IC3;\n•\t Mucinous carcinoma infiltrative stage IC3;\n•\t Small-cell carcinoma hyper calcaemic type;\n•\t Granulosa cell tumour stage IB and II–IV;\n•\t Sertoli-Leydig cell tumours well-and-moderately differentiated at stages\n\nIB and IC2–IV, and poorly differentiated at all stages.\nB\nOncologic selection criteria acceptable in selected cases\nOne of the following criteria should be met:\n•\t Low-grade serous and low-grade endometrioid carcinomas stage IC2;", "section": "Neoadjuvant chemotherapy for selected patients with stage IB2", "page_from": 16, "page_to": 16, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8677e3f1cc4ac0e5c08839ab6de0b934b7251396fe3a7f47a880adb15feac23c"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000031", "text": "B\nOncologic selection criteria acceptable in selected cases\nOne of the following criteria should be met:\n•\t Low-grade serous and low-grade endometrioid carcinomas stage IC2;\n•\t Mucinous carcinoma expansile subtype stage IC3;\n•\t Clear cell carcinoma stage IC2;\n•\t High grade serous and high-grade endometrioid carcinomas stage IC2;\n•\t Mucinous carcinoma infiltrative stage IC1 and IC2;\n•\t Granulosa cell tumour stage IC2 and IC3;\n•\t Sertoli Leydig cell tumours, well differentiated and moderately differen-\n\ntiated at stages IB and IC1;\n•\t Tubo-ovarian carcinoma (unilateral) or serous tubal intraepithelial\n\ncarcinoma in patients younger than 40 years with high-risk predisposition\n\ngermline mutation.\nC", "section": "Neoadjuvant chemotherapy for selected patients with stage IB2", "page_from": 16, "page_to": 16, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f3d3ad55293889d0b8eceecb4ab3026911ed8c1c2855c345e34b742b46d28de6"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000032", "text": "17\nTable 1\nIndications for in vivo ovarian tissue preservation in ovarian\nneoplasms according to the histological type and the stage\nof the disease\nSTAGE\nEPITHELIAL OVARIAN NEOPLASMS\nNON-EPITHELIAL OVARIAN NEOPLASMS\nBOT1\nLGSC\nLGEC\nMCexp\nCCC\nHGSC\nHGEC\nMCinf\nGCT2\nSCC\nGrCT\nSLCT3\nSLCT4\nIA\nIB\nIC1\nIC2\n##\nIC3\n##\nII-IV\n#\n\nfavourable oncologic selection criteria for fertility-sparing management as defined in\nthe text (based on the favourable survival and/or recurrence rates observed in cohorts and/\nor comparative studies (radical versus conservative) of patients treated with such characteris-\ntics).\n\noncologic selection criteria acceptable in selected cases (insufficient or conflicting data\nto evaluate accurately the results of the ovarian preservation in this subgroup of patients).\n\nunfavourable oncologic selection criteria for ovarian preservation (poorest survival\nobserved in patients having an ovarian preservation in these subgroups. It could be related\nto the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).", "section": "Table 1", "page_from": 17, "page_to": 17, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "bbe5b1956bda06bbb25c25e1ddaee7e1cac74aa87278610c3e0bdde673e83dc6"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000033", "text": "to the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).\n1non-invasive peritoneal implants; 2including immature teratoma, dysgerminoma, Yolk-sac\ntumours; 3well and moderately differentiated; 4poorly differentiated; #for grade 2-3 imma-\nture teratoma stage II-IV, fertility-sparing data are limited; ## for Sertoli-Leydig cell tumour\nstage IC2-3, fertility-sparing data are limited.\nBOT borderline ovarian tumour; CCC clear cell carcinoma; GCT germ cell tumour; GrCT\ngranulosa cell tumour; HGEC high-grade endometrioid carcinoma; HGSC high-grade serous\ncarcinoma; LGSC low-grade serous carcinoma; LGEC low-grade endometrioid carcinoma,\nMCexp mucinous carcinoma with expansile invasion, MCinf mucinous carcinoma with in-\nfiltrative invasion; SCC small cell carcinoma; SLCT Sertoli-Leydig cell tumour.", "section": "Table 1", "page_from": 17, "page_to": 17, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a96398aeef0a57fd0e95f7c8585ae6b3e73844d61e0b9083f633f75ccfac23ba"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000034", "text": "18\nSalpingo-oophorectomy vs. cystectomy in selected cases of borderline\novarian tumours\nBilateral ovarian cystectomy with macroscopic healthy ovarian tissue spa-\nring in bilateral serous and seromucinous borderline ovarian tumours can\nbe considered.\nUnilateral salpingo-oophorectomy and cystectomy with macroscopic\nhealthy ovarian tissue sparing are both acceptable strategies for unilateral\nserous and seromucinous borderline ovarian tumour. In case of cystectomy,\npatients should be counselled about the risk of local and ovarian recurrence\nof up to 30% with no effect on overall survival, but better fertility results.\nB\nB\nReproductive medicine specialist consultation\nOptimisation of fertility results and infertility management\nIndividuals who wish to preserve their fertility should be offered repro-\nductive counselling before the beginning of any oncological treatment.\nThe reproductive medicine specialist should be part of the treatment decisi-\non process and be consulted when treatment plans are changing or family\nplanning starts. Creation of a specific multidisciplinary team is encouraged.\nB\nA\nReproductive medicine specialist consultation in patients with ovarian", "section": "Bilateral ovarian cystectomy with macroscopic healthy ovarian tissue spa-", "page_from": 18, "page_to": 18, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b50d86882b3148d8b09b003116e5396e235fb495afeec12c1bf2ad1d42d22386"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000035", "text": "planning starts. Creation of a specific multidisciplinary team is encouraged.\nB\nA\nReproductive medicine specialist consultation in patients with ovarian\ncancer and high-risk genetic predisposition\nPatients who carry a high-risk genetic predisposition for ovarian cancer\nshould have similar fertility preservation counselling compared with non-\n-carriers (see Table 1), including the information about transmission to the\noffspring.\nIf fertility preservation is considered, ovarian stimulation followed by oocyte\nor embryo cryopreservation is the treatment of choice in patients who carry\na high-risk genetic predisposition as it does not increase the individual risk\nof developing new hormone-dependent cancers.\nThere are no data on oncological safety of ovarian tissue reimplantation in\npatients who carry a high-risk genetic predisposition, but cryopreservation\nof ovarian tissue might be considered.\nAfter completion of family planning or at the recommended time of pelvic\nprophylactic surgery, salpingo-oophorectomy, with or without hysterecto-\nmy, should be performed in patients who carry a high-risk genetic predis-\nposition.", "section": "Bilateral ovarian cystectomy with macroscopic healthy ovarian tissue spa-", "page_from": 18, "page_to": 18, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "08008c9b950c85e4ddc49db4b3ed68807fa22b4805636973d37b1cc063eb7bff"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000036", "text": "prophylactic surgery, salpingo-oophorectomy, with or without hysterecto-\nmy, should be performed in patients who carry a high-risk genetic predis-\nposition.\nPatients who carry a high-risk genetic predisposition could be referred for\npreconception and preimplantation genetic-testing counselling.\nA\nB\nC\nB\nC", "section": "Bilateral ovarian cystectomy with macroscopic healthy ovarian tissue spa-", "page_from": 18, "page_to": 18, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5ce7c4e5f0576998a3681f9d95904250e19d8eb1f09c0d5777c0aebe00468984"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000037", "text": "19\nEvaluating ovarian function in patients before cancer treatment\nThe assessment of ovarian reserve should be done with the same methods\nas in women without cancer (eg, serum anti-Müllerian hormone and antral\nfollicle count), although the interpretation of results might be difficult in\npatients with ovarian tumours.\nThe age of the patient is more important than anti-Müllerian hormone and\nantral follicle count in planning fertility-sparing treatment. Pretreatment\novarian reserve markers alone should not be used as treatment guide for\nfertility-sparing surgery.\nB\nD\nFertility preservation methods in first-line treatment settings\nOvarian tumours\nOvarian stimulation followed by egg retrieval can be offered to patients\nwith ovarian cancer with favourable prognostic factors considering histolo-\ngical diagnosis, hormone sensitivity, cancer stage, and oncological progno-\nsis (see Table 1).\nOvarian stimulation followed by egg retrieval for fertility preservation is not\nrecommended before final histological confirmation of a possibly malignant\nor borderline ovarian mass.\nFor primary ovarian neoplasms, it is recommended that ovarian stimulation", "section": "Evaluating ovarian function in patients before cancer treatment", "page_from": 19, "page_to": 19, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "18c6daea91c514f282cd638f618a4a622e33ae9c72ff4a30fe683a3d27864cc4"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000038", "text": "recommended before final histological confirmation of a possibly malignant\nor borderline ovarian mass.\nFor primary ovarian neoplasms, it is recommended that ovarian stimulation\nand oocyte cryopreservation be performed after completing staging surge-\nry and determining the histological diagnosis, hormone sensitivity, cancer\nstage, and oncological prognosis (see Table 1).\nOvarian tissue freezing and immature oocytes retrieval for ex vivo in vitro\nmaturation and further mature oocyte vitrification during surgery in case of\nbilateral oophorectomy could be offered.\nOvarian stimulation followed by oocyte retrieval is not contraindicated in\npatients previously treated for stage I ovarian borderline tumours, even in\ncases of abnormal-appearing residual ovary that will be subjected to stimu-\nlation.\nOvarian stimulation followed by oocyte retrieval (even in cases of abnormal-\n-appearing residual ovary) is not contraindicated in patients with advanced\nstage borderline ovarian tumours, as long as there has been a complete\nresection and pathological evaluation (confirming non-invasive implants) of\nvisible peritoneal lesions.", "section": "Evaluating ovarian function in patients before cancer treatment", "page_from": 19, "page_to": 19, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b0e3db0ea1dacdd8f180d79dbb6d4e8169391bacc40c984ab3333ecf49c01ce5"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000039", "text": "stage borderline ovarian tumours, as long as there has been a complete\nresection and pathological evaluation (confirming non-invasive implants) of\nvisible peritoneal lesions.\nThe timing of ovarian stimulation and egg retrieval when adjuvant chemo-\ntherapy for ovarian cancer is planned depends on multidisciplinary discus-\nsion and can be performed ideally before chemotherapy or in rescue at least\n6 months after chemotherapy (post-treatment fertility preservation).\nC\nB\nD\nB\nD\nC\nD", "section": "Evaluating ovarian function in patients before cancer treatment", "page_from": 19, "page_to": 19, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "dc6b92cd5d75fe03270fc18c87ea3bfbe180820cdcf6ecccdabdfc384f3b1438"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000040", "text": "20\nIn cases of borderline ovarian tumour, biomarkers of the tumour (BRAF,\noestrogen receptor, KRAS, etc) should not be used as a contraindication for\nconsidering ovarian stimulation (indication and protocol).\nIn cases of low-grade serous or ovarian endometrioid adenocarcinoma or\ngranulosa cell tumour, the ovarian stimulation protocol based on co-treat-\nment with aromatase inhibitors should be a first choice (see Table 1).\nD\nB\nCervical cancers\nFor all patients with cervical cancer eligible for fertility-sparing manage-\nment, ovarian stimulation followed by oocyte retrieval can be discussed\nfor women without ovarian involvement treated by radiotherapy, brachy-\ntherapy, or hysterectomy in accordance with the legal country-specific regu-\nlations regarding surrogate pregnancy.\nSpecial attention is needed for ovarian stimulations and transvaginal oocyte\nretrieval in the presence of active cervical neoplasia. Transvaginal punctu-\nre and retrieval might be possible in selected cases with minimal tumour\ninvolvement. However, it should be avoided in cases with extensive upper\nvaginal disease to minimise the theoretical risk of iatrogenic cancer spread", "section": "In cases of low-grade serous or ovarian endometrioid adenocarcinoma or", "page_from": 20, "page_to": 20, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e4e6332bb6cc4c8819f307192b8d64a23e0f635ca2ccd41e7e83f248e6283f16"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000041", "text": "involvement. However, it should be avoided in cases with extensive upper\nvaginal disease to minimise the theoretical risk of iatrogenic cancer spread\nduring the procedure. A transabdominal laparoscopic approach or open\napproach might be an option. Transabdominal approach for oocyte retrieval\nhas been suggested as a safe and efficacious procedure.\nC\nC\nFertility preservation methods in case of recurrence\nFertility evaluation for patients with apparent recurrent, borderline ovarian\ntumours who wish to preserve their fertility is mandatory before any tre-\natment in gynaecological oncology centres with comprehensive multidis-\nciplinary expertise within a multidisciplinary team, including a reproductive\nmedicine specialist.\nOvarian stimulation followed by oocyte retrieval in cases of recurrent stage I\nborderline ovarian tumour with no evidence of peritoneal disease is feasible\nbefore potential definitive surgery.\nOvarian stimulation followed by oocyte retrieval in cases of recurrent advan-\nced stage borderline ovarian tumour is feasible as long as there has been\na complete resection and pathological evaluation (confirming non-invasive", "section": "In cases of low-grade serous or ovarian endometrioid adenocarcinoma or", "page_from": 20, "page_to": 20, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "057d8f2e877a53abc7e3d7fe3045869a33df961907b0183c00a2e81ef9145b9d"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000042", "text": "ced stage borderline ovarian tumour is feasible as long as there has been\na complete resection and pathological evaluation (confirming non-invasive\nimplants) of visible peritoneal lesions and normal-appearing abdominopel-\nvic imaging (CT or MRI scan) suggesting the absence of obvious implants\nbefore the eventual stimulation.\nA\nC\nC", "section": "In cases of low-grade serous or ovarian endometrioid adenocarcinoma or", "page_from": 20, "page_to": 20, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f5f598b155a2342461eed5038994de581a53963e375e2d973bec195972eb27e5"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000043", "text": "21\nFor malignant germ cell tumours, fertility preservation strategy should be\ndiscussed on an individual basis in a multidisciplinary team for women pre-\nviously treated for an immature teratoma and presenting a recurrence high-\nly suspicious of benign teratoma or growing teratoma syndrome.\nIn cases of a suspected recurrence of sex cord tumours, fertility preservation\nstrategies should not be considered.\nB\nD\nEvaluating ovarian function\nIt is important to recognise the limitations of serum anti Müllerian hormone\nconcentrations and antral follicle count as predictors of pregnancy, either\nthrough natural conception or after assisted reproductive technology (ART).\nRegular measurement of serum anti-Müllerian hormone concentrations\nafter cancer treatment can be used to indirectly estimate the degree and\nevolution of the ovarian follicular pool and ovarian response to stimulation.\nB\nC\nWhat should be offered to patients after treatment?\nDesire for immediate pregnancy\nIf fertility-sparing surgery did not affect the possibility of unassisted concep-\ntion, patients are advised to attempt spontaneous conception for at least", "section": "In cases of low-grade serous or ovarian endometrioid adenocarcinoma or", "page_from": 21, "page_to": 21, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "19049d27e31b4a7bb63999767b04ca61f36e308f682dde512ecb8ee0cf5934b6"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000044", "text": "Desire for immediate pregnancy\nIf fertility-sparing surgery did not affect the possibility of unassisted concep-\ntion, patients are advised to attempt spontaneous conception for at least\n6 months before being referred to a reproductive medicine specialist. Pa-\ntients with a history of infertility or inability to conceive spontaneously\nshould be referred to a reproductive medicine specialist as soon as possible.\nB\nNo immediate pregnancy desired\nPatients treated for ovarian tumours could be referred to a reproductive\nmedicine specialist for counselling.\nIn case of a previous history of infertility or inability of natural conception\ndue to surgery, patients should be referred to a reproductive medicine spe-\ncialist to discuss oocyte or embryo freezing.\nPatients who underwent fertility-sparing surgery for borderline ovarian\ntumours, including those with micropapillary or microinvasive features\n(who still have at least one ovary), should be advised about the availability\nof reproductive medicine specialists and referred as needed (see Table 1).\nPatients who underwent fertility-sparing surgery for ovarian cancer (who still", "section": "In cases of low-grade serous or ovarian endometrioid adenocarcinoma or", "page_from": 21, "page_to": 21, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "41029cfdbbfe1276a65f33eecc6ed0366a235443c715c4fa646b4a96ab5ffde8"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000045", "text": "of reproductive medicine specialists and referred as needed (see Table 1).\nPatients who underwent fertility-sparing surgery for ovarian cancer (who still\nhave at least one ovary) and are considered to have a favourable oncological\nprognosis should be advised about the availability of reproductive medicine\nspecialists and referred if applicable, taking into account histological dia-\ngnosis, hormone sensitivity, stage, and oncological prognosis (see Table 1).\nC\nB\nB\nB", "section": "In cases of low-grade serous or ovarian endometrioid adenocarcinoma or", "page_from": 21, "page_to": 21, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3deb5d821da46a987a8d00259e75feb5544185f20e022cc2e81bc85bdfdeb55e"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000046", "text": "22\nOocyte vitrification\nWhen oocyte vitrification is considered after fertility-sparing surgery alone,\novarian reserve assessment should be performed at least 6 months after\nsurgery to allow recovery.\nWhen oocyte vitrification is considered after chemotherapy, ovarian re-\nserve assessment should be performed after at least 6 months.\nB\nB\nWhen should oncological authorisation be granted?\nDesire for a pregnancy and beyond\nA\nC\nAll patients with borderline ovarian, epithelial, or non-epithelial tumours\nshould be advised according to the age of the patient, stage of disease,\npathology, unilateral or bilateral localisation of the tumour, and mode of\nsurgery (eg, cystectomy vs oophorectomy).\nPatients with cervical cancer treated with any kind of surgery (eg, trache-\nlectomy or conisation) are advised not to attempt pregnancy within the\nfirst 6 months after surgery.\nSpontaneous pregnancies can be encouraged in patients with a borderline\novarian tumour immediately after the fertility-sparing surgery.\nPatients needing fertility treatment can be referred for ART in cases of\na low-stage borderline ovarian tumour immediately after fertility-sparing\nsurgery.", "section": "Oocyte vitrification", "page_from": 22, "page_to": 22, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "514def757e163594fac0ddbfbb8aa5290ac4b33b3ae12710b9abcacad13b84f2"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000047", "text": "Patients needing fertility treatment can be referred for ART in cases of\na low-stage borderline ovarian tumour immediately after fertility-sparing\nsurgery.\nPatients needing fertility treatment can be referred for ART in cases of\nadvanced-stage borderline ovarian tumour after complete resection and ab-\nsence of invasiveness of implants immediately after fertility-sparing surgery.\nPatients with a borderline ovarian tumour at high risk of relapse could be\nreferred immediately after fertility-sparing surgery for oocyte or embryo\ncryopreservation.\nPatients with epithelial ovarian cancer might be advised to become preg-\nnant 1 year after the completion of treatment with negative follow-up.\nPatients with non-epithelial, early-stage ovarian cancer might be advised\nto become pregnant after the first 6 months of a negative follow-up after\nthe fertility-sparing procedure.\nFor patients with non-epithelial ovarian cancer needing fertility treatment,\nART can be performed after the first 6 months of a negative follow-up\nafter the fertility-sparing procedure.\nRegardless of cancer type, patients should be advised that they are not\nlimited to one pregnancy.\nB\nB\nB\nC\nC\nC\nC\nA", "section": "Oocyte vitrification", "page_from": 22, "page_to": 22, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9eb9275b787a900911bef671ad09a6c7bac9eddd8c42d2292fb0b90d199728ad"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000048", "text": "23\nCervical cancer\nFrequencies of follow-up after fertility-sparing management\nFollow-up is the same as for any patient with cervical cancer; namely, every\n3–4 months for 2 years, every 6 months for another 3–5 years, and then\nannually.\nReduction of frequency of follow-up could be proposed in cases of negative\nHPV testing after conservative surgery.\nB\nC\nFollow-up procedures after fertility-sparing management\nPhysical examination should be performed, including bimanual pelvic exa-\nmination every 3-4 months for the first 2 years, every 6 months thereafter\nuntil the fifth year, and then annually. Cytology plus HPV testing should be\nperformed after 6 months, then annually.\nColposcopy should be performed in cases of abnormalities at cytology and\na biopsy sample should be taken for positive results from HPV testing.\nHPV vaccination should be encouraged.\nMRI (preferably evaluated by a dedicated gynaecological radiologist) is\nmandatory at 6 months and 12 months, and then when clinically indicated\nthereafter.\nTransvaginal ultrasonography, with or without transrectal ultrasonography,\nis an option when performed by an experienced sonographer.", "section": "Cervical cancer", "page_from": 23, "page_to": 23, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "45564cc64b7b362984550b548cdc543c7aec1d245bcd42e616773b5824895434"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000049", "text": "thereafter.\nTransvaginal ultrasonography, with or without transrectal ultrasonography,\nis an option when performed by an experienced sonographer.\nPET-CT can be considered in cases of suspicion of a recurrence.\nThere is no evidence to recommend the routine use of squamous cell carci-\nnoma antigen in follow-up.\nB\nB\nC\nC\nB\nA\nB\nSpecific requirements for the follow-up during the pregnancy and\nmaternal surveillance\nA surgery requiring a large cervical excision should be accompanied by a\npermanent cerclage.\nProgesterone supplementation in pregnancy after fertility-sparing surgery\nfor cervical cancer is recommended to prevent preterm birth.\nPatients with and without a permanent cerclage should be assessed for\ncervical incompetence during pregnancy by an experienced obstetrician.\nPatients treated only with a large or repeat conisation should be evaluated\nfor cervical incompetence or competence by an experienced obstetrician.\nB\nB\nB\nB", "section": "Cervical cancer", "page_from": 23, "page_to": 23, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "23fc6f7bd88b5950f157451108e2dcd05183a9bb66388195181b20476c7f4aa0"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000050", "text": "24\nMRI can be performed when clinically relevant.\nFollow-up visit consists of a physical examination and cytology plus HPV\ntesting (co-testing) in early pregnancy unless it was performed within the\nlast year.\nColposcopy should be performed when indicated from cytology or HPV\ntesting and from clinical implications.\nTransvaginal ultrasonography, with or without transrectal ultrasonography,\nshould be performed by an experienced sonographer when clinically indi-\ncated.\nElective caesarean section should be considered for delivery in patients with\nhistory of invasive cervical cancer.\nBreastfeeding is recommended, as in the general population, and should\nnot be discouraged.\nB\nB\nA\nB\nB\nB\nNeed for completion surgery after childbearing\nCompletion surgery after childbearing with no evidence of disease is not\nrecommended.\nHysterectomy should be offered only in cases where follow-up is not feasib-\nle (cervical stenosis and patient incompliance) and in cases of persistent,\nhigh-risk, HPV-positive test results.\nB\nD\nIndication and modalities for hormone replacement therapy after\ncompletion surgery or bilateral salpingo-oophorectomy plus uterine\npreservation", "section": "Follow-up visit consists of a physical examination and cytology plus HPV", "page_from": 24, "page_to": 24, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "78247b805824ec4598166dccbb8b8a91a670c2ea680730ca8359ee38840e7ea1"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000051", "text": "high-risk, HPV-positive test results.\nB\nD\nIndication and modalities for hormone replacement therapy after\ncompletion surgery or bilateral salpingo-oophorectomy plus uterine\npreservation\nPatients with premature ovarian insufficiency after treatment of squamous\ncell cervical cancer can be offered hormone replacement therapy after dis-\ncussing risks and benefits.\nIn patients with adenocarcinoma positive for oestrogen receptors, hormo-\nne replacement therapy could be offered on an individual basis after tho-\nrough discussion.\nC\nC\nOvarian cancer\nFrequencies of follow-up after fertility-sparing management\nFollow-up is recommended every 3–4 months for 2 years, every 6 months\nfor another 3–5 years, and then annually for at least 10 years.\nFollow-up should consist of physical examination and ultrasound examina-\ntion by an experienced ultrasonographer.\nB\nB", "section": "Follow-up visit consists of a physical examination and cytology plus HPV", "page_from": 24, "page_to": 24, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b8085e723b9e42d33adb91caee66c3733636c988d2e300a1ece71f45ee97b798"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000052", "text": "25\nPelvic and abdominal CT or MRI should be performed at 6 months and then\nannually until the fifth year.\nMeasurement of cancer antigen-125 concentration or other tumour mar-\nkers according to histotype (ie, inhibin B, anti-Müllerian hormone for sex\ncord stromal tumours, β-human chorionic gonadotrophin, α-fetoprotein, or\nlactate dehydrogenase for germ cell tumours) is only recommended when\ninitially elevated or when presurgical markers are missing.\nPET-CT is only indicated in cases of suspicion of recurrence.\nB\nB\nB\nSurveillance during pregnancy\nTransvaginal and abdominal ultrasonography should be performed by an\nexperienced sonographer in early first and second trimester of pregnancy.\nFollow-up of tumour markers is not recommended during pregnancy.\nBreastfeeding is recommended as in the general population and should not\nbe discouraged.\nB\nB\nD\nNeed for a completion surgery after childbearing\nRoutine completion surgery (removal of remaining ovary and tube) is not\nrecommended in patients with borderline ovarian tumours.\nRoutine completion surgery is recommended in patients with a family his-\ntory of genetic high-risk epithelial ovarian tumours.", "section": "Pelvic and abdominal CT or MRI should be performed at 6 months and then", "page_from": 25, "page_to": 25, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c526c6a1bbe7101b59703cdf9a3443423fba815ae6e87c62b6a4580aeb96e274"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000053", "text": "recommended in patients with borderline ovarian tumours.\nRoutine completion surgery is recommended in patients with a family his-\ntory of genetic high-risk epithelial ovarian tumours.\nRoutine completion surgery could be considered on a case-by-case basis in\npatients with epithelial ovarian tumours.\nRoutine completion surgery is not recommended in patients with germ cell\ntumours.\nIn all other non-epithelial tumours, routine completion surgery could be\noffered on a case-by-case basis.\nIn patients with granulosa cell tumours, additional hysterectomy must be\nconsidered.\nD\nB\nC\nD\nC\nB\nIndications and modalities for hormone replacement therapy after\ncompletion surgery or bilateral salpingo-oophorectomy plus uterine\npreservation\nHormone replacement therapy can be offered after completion surgery to\npatients with borderline ovarian tumours and ovarian cancer after discuss-\ning risks and benefits and taking into account their histological subtype.\nB", "section": "Pelvic and abdominal CT or MRI should be performed at 6 months and then", "page_from": 25, "page_to": 25, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2903f1e446e2029aa3b70be3cf7bc1c940a97c44fc101753c2b99015fa5869c2"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000054", "text": "26\nNOTES", "section": "NOTES", "page_from": 26, "page_to": 26, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "09db81fed01551a80d5b375fc51f3a538d5f67ac96d57d0e0616c4bed47f4780"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000055", "text": "27\nAccess full ESGO Guidelines: www.esgo.org/explore/guidelines\n© 2025 European Society of Gynaecological Oncology\nAll rights reserved. No part of this book can be reprinted, reproduced, transmitted or utilised in any\nform by any electronic, mechanical, or other means, now known or hereafter invented, including\nphotocopying, microfilming, and recording, or any information storage or retrieval system, without\nwritten permissions of ESGO. Reasonable efforts have been made to publish reliable data and\ninformation, but the authors and publisher cannot assume responsibility for the validity of all mate-\nrials or for the consequences of their use, and the ultimate responsibility rests with the prescribing\nphysician.", "section": "NOTES", "page_from": 27, "page_to": 27, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "70088889c4c9b753815bb490625dc442fa0f73e1b6052ab9c6d7e618e77a3358"}
{"doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000", "chunk_id": "000056", "text": "© 2025 European Society of Gynaecological Oncology. All rights reserved.\nEuropean Society of Gynaecological Oncology\nAvenue Emmanuel Mounier, 83/11\n1200 Brussels, Belgium\nEmail: adminoffice@esgomail.org\nwww.esgo.org", "section": "European Society of Gynaecological Oncology", "page_from": 28, "page_to": 28, "display_name": "ESGO_ESHRE_ESGE_FertilitySparing_Pocket_2025", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c5fa0de3d23f4cfc53b6f86ed36b0f2133e6d602b904672f6e0a3e0bbcb3dd17"}
